IGF2BP1 and rhabdomyosarcoma: Along these lines, it appears reasonable that IGF2BP1 supports MYC/N-driven proliferation capacity in embryonal neuroblasts, other childhood/youth cancers with strong MYC/N-dependency and aberration at Chr 17q, e.g. rhabdomyosarcoma and medulloblastoma, as well as carcinomas in general.